News Focus
News Focus
Followers 1
Posts 173
Boards Moderated 0
Alias Born 08/11/2016

Re: Honeycomb777 post# 5386

Wednesday, 02/08/2017 1:02:57 PM

Wednesday, February 08, 2017 1:02:57 PM

Post# of 20617
This is a waiting game and the longer it drags on the more likely is a further drop in share price. But speculating about where this bottoms out or not is really superfluous as one guess is as good (or bad) as another.

What is for sure is that this period belongs to the voices of the pessimists. Don't let yourself upset by it. Once we get FDA approval all the good news we had in the past which had no noticable influence on the share price will then have a delayed effect.
It's really unfortunate that this stock has thus far hinged on FDA approval, but that's how the stock is perceived and I'm OK with that since approval is only a matter of WHEN, not IF. The absolute worst case scenario would be a CLR because of some formality issues.

I also find most points of critism about Dr. D unfounded. He is certainly not diluting this stock for poor reasons. He needs cash on hand in order to be able to commercialize FlutiCare and this has always been expected. Where else should he have gotten the required money from? This is after all still an early stage pharmaceutical company which just recently managed to become cashflow positive. I ask all the critics and armchair CEOs to make better suggestions instead of just screaming that Dr. D. is a poor businessman. That way you they would at least give some credibility to their statements. But this is usually when the critics get silent as any suggestion would reveal that they have no idea about how to run a business.

By the way, the market supports the view that the latest offering wasn't a bad business move. Otherwise we would have seen a sharp drop in share price and that absolutely didn't happen! If I hear the pessimists constantly say the same "the market is always right" then they should at least acknowledge that this time the market doesn't consider the latest S-1 a problem. The same goes for the premature issuance of the Novalere shares!

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today